<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>316</serviceExecutionTime><Drug id="8922"><DrugName>BAY-10-8039</DrugName><DrugNamesKey><Name id="42759288">talviraline</Name></DrugNamesKey><DrugSynonyms><Name><Value>HBY-097</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>talviraline</Value><Types><Type>USAN</Type></Types></Name><Name><Value>BAY-10-8039</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>BAY-10-8979</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>163451-80-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="25218">Aventis Pharma AG</CompanyOriginator><CompaniesSecondary><Company id="14455">Bayer AG</Company><Company id="16453">Glaxo Group Ltd</Company><Company id="25224">Hoechst Marion Roussel Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="8922" type="Drug"><TargetEntity id="215948" type="siDrug">Talviraline</TargetEntity></SourceEntity><SourceEntity id="14455" type="Company"><TargetEntity id="4295869217" type="organizationId">Bayer AG</TargetEntity></SourceEntity><SourceEntity id="16453" type="Company"><TargetEntity id="5000022355" type="organizationId">Glaxosmithkline Services Unlimited</TargetEntity></SourceEntity><SourceEntity id="25218" type="Company"><TargetEntity id="4296758779" type="organizationId">Aventis Pharma AG</TargetEntity></SourceEntity><SourceEntity id="25224" type="Company"><TargetEntity id="4295910625" type="organizationId">Aventis Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="158" type="ciIndication"><TargetEntity id="B20" type="ICD10"/><TargetEntity id="042" type="ICD9"/><TargetEntity id="10020161" type="MEDDRA"/><TargetEntity id="D015658" type="MeSH"/><TargetEntity id="-841965209" type="omicsDisease"/><TargetEntity id="862" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="158">HIV infection</Indication></IndicationsSecondary><ActionsPrimary><Action id="1833">Non-nucleoside reverse transcriptase inhibitor</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J5C3</Code><Name>Non-nucleoside reverse transcriptase inhibitors</Name></Ephmra></EphmraCodes><LastModificationDate>2017-11-28T10:10:50.000Z</LastModificationDate><ChangeDateLast>2017-02-22T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="26089" linkType="Company"&gt;Hoechst&lt;/ulink&gt; (now Aventis Pharma) and &lt;ulink linkID="14455" linkType="Company"&gt;Bayer&lt;/ulink&gt; were developing the quinoxaline talviraline as a potential therapy for HIV infection. The compound had been had been licensed to Glaxo Wellcome. However, all three companies have now discontinued development of talviraline [&lt;ulink linkID="278836" linkType="reference"&gt;278836&lt;/ulink&gt;], [&lt;ulink linkID="364127" linkType="reference"&gt;364127&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The compound had undergone phase II trials in Europe and the US. Dose-escalating phase II trials evaluated 150 HIV patients with CD4 cell counts of 200 to 500/mm3. Patients received talviraline at 125, 250, 375, 500 or 750 mg tid for 7 days [&lt;ulink linkID="227903" linkType="reference"&gt;227903&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;This non-nucleoside reverse transcriptase inhibitor has good bioavailability and tolerability in healthy volunteers according to results from preliminary phase I trials. Clinically relevant drug levels (based upon in vitro data) have been achieved [&lt;ulink linkID="169513" linkType="reference"&gt;169513&lt;/ulink&gt;]. The only side effect in phase I trials was slight neutropenia [&lt;ulink linkID="184452" linkType="reference"&gt;184452&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The potential drug interaction of talviraline with &lt;ulink linkID="5321" linkType="Drug"&gt;indinavir&lt;/ulink&gt; and &lt;ulink linkID="44316" linkType="Drug"&gt;zidovudine&lt;/ulink&gt; has been evaluated in a pharmacokinetic study in eight HIV subjects. Results showed that there was no significant change in the AUC of &lt;ulink linkID="44316" linkType="Drug"&gt;zidovudine&lt;/ulink&gt;. However, the clearance and bioavailability of &lt;ulink linkID="5321" linkType="Drug"&gt;indinavir&lt;/ulink&gt; was significantly higher after 11 days of concomitant administration with talviraline. The study demonstrated that a pharmacokinetic drug interaction exists between &lt;ulink linkID="5321" linkType="Drug"&gt;indinavir&lt;/ulink&gt; and talviraline, where talviraline induces CYP3A4 metabolism of &lt;ulink linkID="5321" linkType="Drug"&gt;indinavir&lt;/ulink&gt; resulting in a decreased plasma concentration [&lt;ulink linkID="283895" linkType="reference"&gt;283895&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A combination of talviraline and 3TC has been tested in CEM cells infected with AZT-resistant HIV-1 strains, and proved effective at suppressing viral breakthrough at concentrations as low as 2.5 and 50 ng/ml, for talviraline and 3TC, respectively [&lt;ulink linkID="243409" linkType="reference"&gt;243409&lt;/ulink&gt;], [&lt;ulink linkID="247057" linkType="reference"&gt;247057&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Talviraline is not the preferred candidate for future development. However, follow-on quinoxalines (qv) that may have disadvantages over talviraline are at an early stage of development [&lt;ulink linkID="278836" linkType="reference"&gt;278836&lt;/ulink&gt;]. Talviraline displays good potency against P236L and Y181C RT enzymes, but selected for a mutant G190E RT in passaging experiments [&lt;ulink linkID="293158" linkType="reference"&gt;293158&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;Tahir Malik, &lt;ulink linkType="Company" linkID="27527"&gt;Salem-Teikyo University&lt;/ulink&gt;, Salem, WV 26426-0500, USA&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;15 September 1997&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;The reverse transcriptase (RT) gene of HIV is a crucial component of its life cycle, since it is required to convert the viral RNA into a double-stranded DNA copy before the viral genetic information can be integrated into the host genomic DNA. Several nucleoside analog drugs, which inhibit the RT of HIV, are already available on the market. These include AZT, ddC, ddA and ddI. AZT has been extensively used to treat HIV infected patients, but serious side-effects have been observed, such as bone marrow suppression. New non-nucleoside drugs are currently under development and include&lt;br/&gt;bis(heteroaryl)piperazines (BHAPS), pyridinone derivatives, and quinoxaline derivatives. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;HBY-097  (3,4-dihydro-8-methoxy-2-((methylthio)methyl)-3-thioxo-1(2H)-quinoxaline carboxylic acid, 1-methylether ester) is a quinoxaline-derived non-nucleoside reverse transcriptase inhibitor (NNRTI) [&lt;ulink linkType="reference" linkID="201250"&gt;201250&lt;/ulink&gt;]. Although quinoxaline-derived NNRTI's belong to a different chemical class from other NNRTI's, they bind to a common hydrophobic pocket of the p66 subunit of the RT. NNRTI resistant HIV-1strains arise due to mutations in the hydrophobic pocket [&lt;ulink linkType="reference" linkID="222202"&gt;222202&lt;/ulink&gt;]. Furthermore, like other NNRTI's, quinoxaline-derived NNRTI's do not inhibit the HIV-2 RT. HBY-097 has been designated as a medium priority project by Hoechst-Roussel and if these priorities are not met, the project will be discontinued.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;The experimental data for HBY-097 indicate rapid absorption of the drug. However, HBY-097 shows a high protein binding capacity (&gt; 95%), which means that only 1 - 2% may be available for intracellular distribution in patients [&lt;ulink linkType="reference" linkID="222201"&gt;222201&lt;/ulink&gt;]. The extensive protein binding of the drug could significantly affect the patients since it may be unavailable for intracellular use, or it may serve to maintain the drug in the plasma over a longer period of time and thus provide extended HIV activity. It is important to determine the pharmacokinetic parameters for HBY-097, since the lowering of selective drug pressure results in avoidance of the detrimental mutation at position 190 (G to E). Although this mutation allows HIV-1 to become resistant to the drug, these HIV-1 RT mutants display retarded growth properties [&lt;ulink linkType="reference" linkID="222202"&gt;222202&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;Early studies of the drug in mice and dogs, showed good oral bioavailability [&lt;ulink linkType="reference" linkID="201250"&gt;201250&lt;/ulink&gt;], and according to reports at the International Conference of AIDS in 1996, the drug is rapidly absorbed in asymptomatic and mildly symptomatic patients [&lt;ulink linkType="reference" linkID="222201"&gt;222201&lt;/ulink&gt;]. Furthermore, according to preliminary phase I trial data from Hoechst and &lt;ulink linkType="Company" linkID="14455"&gt;Bayer&lt;/ulink&gt;, the drug has good oral bioavailability and tolerability in healthy volunteers [&lt;ulink linkType="reference" linkID="169513"&gt;169513&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;In almost all clinical trials, very little side-effects have been reported with HBY-097 administration. The only side-effect reported in one phase I trial was slight neutropenia [&lt;ulink linkType="reference" linkID="184452"&gt;184452&lt;/ulink&gt;]. In a study involving asymptomatic and mildly symptomatic HIV positive patients, only two out of nine patients developed a maculopapular rash at the highest dose (750 mg) [&lt;ulink linkType="reference" linkID="222201"&gt;222201&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;In a study of HBY-097, asymptomatic and mildly symptomatic HIV positive patients, with CD4 counts between 200 and 500 cells/mm3, were administered with oral doses of 125, 250, 375, 500, and 750 mg, tid, for seven days for all doses, except at 750 mg, which was administered for 14 days. Clinically relevant trough concentrations were obtained at doses of 250, 500, and 750 mg. Furthermore, a significant viral load reduction was observed at an oral dose of 750 mg, tid [&lt;ulink linkType="reference" linkID="222201"&gt;222201&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a double-blind, dose-escalating phase I study involving 59 patients, plasma viral load was efficiently suppressed (up to -1.38 log10) at all doses tested (125, 250, 750, and 1000 mg) [&lt;ulink linkType="reference" linkID="251814"&gt;251814&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;HBY-097 is currently in phase II trials in both the US and Europe.&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;Phase I trials of HBY-097 have been completed and the results are promising. The drug is well tolerated and shows good oral bioavailability and absorbance. Furthermore, very few side-effects have been reported. As with any other NNRTI, there is the possibility of HIV-resistant strains developing under monotherapy. The efficacy of HBY-097 in combination with 3TC has been studied using HIV-1 infected CEM cells. The multi-drug treatment suppressed viral breakthrough at concentrations of 2.5 and 50 ng/ml for HBY-097 and 3TC respectively [&lt;ulink linkType="reference" linkID="243409"&gt;243409&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="247057"&gt;247057&lt;/ulink&gt;]. Combination therapy, involving RT and protease inhibitors, is currently the treatment of choice by physicians.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate>1999-01-06T00:00:00.000Z</StatusDate><Source id="278836" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate>1999-01-06T00:00:00.000Z</StatusDate><Source id="278836" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate>1999-01-06T00:00:00.000Z</StatusDate><Source id="278836" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16453">Glaxo Group Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate>2000-04-27T00:00:00.000Z</StatusDate><Source id="364127" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate>1996-08-01T00:00:00.000Z</StatusDate><Source id="222202" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate>1996-08-01T00:00:00.000Z</StatusDate><Source id="222202" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25224">Hoechst Marion Roussel Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><Source id="222209" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16453">Glaxo Group Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate>1999-01-06T00:00:00.000Z</StatusDate><Source id="278836" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate>1997-01-27T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><Source id="222209" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01684"><Name>Reverse transcriptase</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Licensing information updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="14455">Bayer AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>1</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC(C)OC(=O)N1c2cc(ccc2NC(=S)[C@@H]1CSC)OC</Smiles></StructureSmiles><Deals><Deal id="121322" title="Bayer and Aventis Pharma to co-develop quinaxolines"/><Deal id="121323" title="Glaxo Wellcome acquires Bayer and HMR's quinaxolines"/></Deals><PatentFamilies><PatentFamily id="1241655" number="EP-00728481" title="Use of quinoxaline and protease inhibitors in a composition for the treatment of AIDS and/or HIV infections."/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayer AG" id="14455"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>